



Jaguar Animal Health to Host Analyst and Investor Day on November 16, 2015 in New York City

October 26, 2015

SAN FRANCISCO--(BUSINESS WIRE)--Oct. 26, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it will host its first Analyst and Investor Day on Monday, November 16, 2015 in New York City.

Members of Jaguar's management team along with third-party key opinion leaders will host a series of presentations beginning at 1:00PM eastern. The event, along with supporting materials, will be accessible via an archived replay through the Jaguar investor relations website at <http://investors.jaguaranimalhealth.com/>.

Space for the event is limited and advanced registration is required. Analysts and institutional investors interested in attending the event should contact Allison Soss at asoss@kcsa.com to register.

About Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Canalevia™ is Jaguar's lead prescription drug product candidate for the treatment of various forms of diarrhea in dogs. Neonorm™ Calf is the Company's lead non-drug product. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the *Croton lechleri* tree, which is sustainably harvested. Neonorm™ is a standardized botanical extract derived from the *Croton lechleri* tree. Canalevia and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has filed nine Investigational New Animal Drug applications, or INADs, with the U.S. FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, and formulations of Canalevia for cats, horses and dogs.

For more information, please visit www.jaguaranimalhealth.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's intention to develop species-specific formulations of Neonorm™ in six additional target species, and Jaguar's planned development of formulations of Canalevia™ for cats, horses, and dogs. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Jaguar-JAGX

View source version on businesswire.com: <http://www.businesswire.com/news/home/20151026005752/en/>

Source: Jaguar Animal Health, Inc.

KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com

or
Allison Soss, 212-896-1267
asoss@kcsa.com